Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 9
Submit an article Journal homepage
7,326
Views
5
CrossRef citations to date
0
Altmetric
Theme: Migraine & Headache - Editorial

Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences

Peer C Tfelt-HansenDepartment of Neurology, Danish Headache Center, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark+45 3863 3050+45 3863 [email protected]
Pages 961-963 | Published online: 09 Jan 2014

References

  • Humphrey PPA. The discovery and development of the triptans, a major therapeutic breakthrough. Headache 48(5), 685–687 (2008).
  • Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment ofbmigraine. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, KMA W ( Eds). Lippincott Williams & Wilkins, Philadelphia, USA, 469–503 (2006).
  • Tfelt-Hansen PC, Koehler P. History of the use of ergotamine and dihydroergotamine in migraine from1906 and forward. Cephalalgia 28, 877–886 (2008).
  • Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60, 1259–1287 (2000).
  • Reddy DS. The pathophysiological and pharmacological basis of current drug treatment of migraine headache. Expert Rev. Clin. Pharmacol. 6(3), 271–288 (2013).
  • Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA ( Eds). Lippincott Williams & Wilkins, PA, USA, 459–467 (2006).
  • Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 53, 180–184 (1996).
  • Tfelt-Hansen P. Unpublished sumatriptan clinical trials. Lancet 374, 1501–1502 (2009).
  • Lipton RB, Hamelsky SW, Dayno M. What do patients with migraine want from acute migraine treatment? Headache 42( Suppl. 1), 3–9 (2002).
  • Shrewsbury SB, Cook RO, Taylor G et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache 48, 355–367 (2008).
  • Aurora SK, Silberstein SD, Kori SH, et al. MAP0004. Orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 51, 507–517 (2011).
  • Tfelt-Hansen P. Relatively slow and long lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review. Cephalalgia doi:10.1177/0333102413483372 (2013) Epub ahead of print).
  • Tfelt-Hansen P. What can be learned from the history of recurrence? A comment. J. Headache Pain 10, 311–415 (2009).
  • Tfelt-Hansen P, Seidelin K, Stepanavage M, Lines C. The effect of rizatriptan, ergotamine, and their combinationon human peripheral arteries: A double-blind, placo- controlled, crossover study in normal subjects. Br. J. Clin. Pharmacol. 54, 38–44 (2002).
  • MaassenVanDenBrink A, Reekers M, Bax WA et al. Coronary side effect potential of current and prospective antimigraine drugs. Circulation 98, 25–30 (1998).
  • Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1(8598), 1309–1311 (1988).
  • Queiroz LP, Weeks RE, Rapoport AM, Sheftell FD, Baskin SM, Siegel SL. Early and transient side effects after repetitive intravenous dihydroergotamine. Headache 36(5), 291–294 (1996).
  • Tfelt-Hansen P, Saxena PR, Ferrari MD. Ergot alkaloids. In: Handbook of Clinical Neurology: Intoxications of the Nervous System. Part II. de Wolf FA ( Ed). Elsevier Science B.V., Amsterdam, The Netherlands, 61–78 (1995).
  • Kori S, Zhang J, Kellerman D et al. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. [Abstract] Conference Programme. European Headache and Migraine Trust International Congress. London, UK, 102 (2012).
  • Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294), 1668–1675 (2001).
  • Tfelt-Hansen P, Saxena PR, Dahlof C et al. Ergotamine in the acute treatment of migraine-European Consensus. Brain 123, 9–18 (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.